Overview Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis Status: Completed Trial end date: 2020-03-13 Target enrollment: Participant gender: Summary Study to evaluate the efficacy and safety of JTE-451 administered for 16 weeks in subjects with moderate to severe plaque psoriasis. Phase: Phase 2 Details Lead Sponsor: Akros Pharma Inc.